Omeros Co. (NASDAQ:OMER) was the target of a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 8,251,440 shares, an increase of 17.3% from the January 12th total of 7,034,714 shares. Based on an average daily volume of 679,248 shares, the short-interest ratio is presently 12.1 days. Currently, 18.3% of the shares of the stock are sold short.
Several equities analysts have recently issued reports on the stock. Maxim Group set a $24.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Wednesday, January 3rd. HC Wainwright set a $30.00 price target on shares of Omeros and gave the company a “buy” rating in a research note on Thursday, January 4th. Zacks Investment Research raised shares of Omeros from a “hold” rating to a “strong-buy” rating and set a $22.00 price target for the company in a research note on Thursday, October 19th. Wedbush reaffirmed an “outperform” rating and set a $47.00 price target on shares of Omeros in a research note on Tuesday, November 28th. Finally, ValuEngine raised shares of Omeros from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Five investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. Omeros currently has a consensus rating of “Buy” and an average price target of $34.14.
Omeros (NASDAQ OMER) traded up $0.10 during mid-day trading on Friday, hitting $14.09. 1,299,301 shares of the stock traded hands, compared to its average volume of 738,924. The company has a market capitalization of $664.13, a P/E ratio of -10.92 and a beta of 3.30. Omeros has a 12-month low of $10.51 and a 12-month high of $27.09. The company has a debt-to-equity ratio of 8.99, a current ratio of 4.77 and a quick ratio of 4.74.
Several institutional investors and hedge funds have recently bought and sold shares of OMER. Ingalls & Snyder LLC increased its position in shares of Omeros by 3.4% during the fourth quarter. Ingalls & Snyder LLC now owns 5,335,239 shares of the biopharmaceutical company’s stock worth $103,664,000 after buying an additional 174,204 shares during the period. Chicago Equity Partners LLC increased its position in shares of Omeros by 268.3% during the third quarter. Chicago Equity Partners LLC now owns 195,875 shares of the biopharmaceutical company’s stock worth $4,235,000 after buying an additional 142,695 shares during the period. First Trust Advisors LP acquired a new stake in shares of Omeros during the fourth quarter worth $2,057,000. Vanguard Group Inc. increased its position in shares of Omeros by 5.4% during the second quarter. Vanguard Group Inc. now owns 1,825,671 shares of the biopharmaceutical company’s stock worth $36,341,000 after buying an additional 94,280 shares during the period. Finally, State Street Corp increased its position in shares of Omeros by 7.3% during the second quarter. State Street Corp now owns 987,057 shares of the biopharmaceutical company’s stock worth $19,652,000 after buying an additional 66,827 shares during the period. Institutional investors own 50.23% of the company’s stock.
Omeros Company Profile
Omeros Corporation is a biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market, as well as orphan indications targeting inflammation, coagulopathies and disorders of the central nervous system. Its marketed drug product, Omidria (phenylephrine and ketorolac injection), is used during cataract surgery or intraocular lens (IOL) replacement.
Receive News & Ratings for Omeros Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omeros and related companies with MarketBeat.com's FREE daily email newsletter.